relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.

Hinow P, Wang SE, Arteaga CL, Webb GF
Theor Biol Med Model. 2007 4: 14

PMID: 17407594 · PMCID: PMC1852549 · DOI:10.1186/1742-4682-4-14

BACKGROUND - Oncogene signaling is known to deregulate cell proliferation resulting in uncontrolled growth and cellular transformation. Gene amplification and/or somatic mutations of the HER2/Neu (ErbB2) proto-oncogene occur in approximately 20% of breast cancers. A therapeutic strategy that has been used to block HER2 function is the small molecule tyrosine kinase inhibitor lapatinib. Using human mammary epithelial cells that overexpress HER2, we determined the anti-proliferative effect of lapatinib through measuring the total cell number and analyzing the cell cycle distribution. A mathematical model was used to interpret the experimental data.

RESULTS - The model suggests that lapatinib acts as expected by slowing the transition through G1 phase. However, the experimental data indicated a previously unreported late cytotoxic effect, which was incorporated into the model. Both effects depend on the dosage of the drug, which shows saturation kinetics.

CONCLUSION - The model separates quantitatively the cytostatic and cytotoxic effects of lapatinib and may have implications for preclinical studies with other anti-oncogene therapies.

MeSH Terms (8)

Cell Cycle Cell Proliferation Cells, Cultured Lapatinib Models, Statistical Protein Kinase Inhibitors Quinazolines Receptor, ErbB-2

Connections (1)

This publication is referenced by other Labnodes entities: